公开(公告)号：US11203595B2

公开(公告)日：2021-12-21

申请号：US16941395

申请日：2020-07-28

Applicant: NOVARTIS AG

Inventor： Badry Bursulaya ,  Andreas Fisch ,  James Paul Lajiness ,  Rainer Machauer ,  Swapnil Malekar ,  Hank Michael James Petrassi ,  Farshad Ramazani ,  Anne-Catherine Remond ,  Thomas Ullrich ,  Peggy Usselmann ,  Eric Vangrevelinghe

IPC: C07D471/04 ,  A61K9/19 ,  A61P21/00 ,  A61K9/00 ,  A61K9/50 ,  A61K31/437 ,  A61K31/496 ,  A61K31/538

Abstract: The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

公开(公告)号：US10112907B2

公开(公告)日：2018-10-30

申请号：US15711984

申请日：2017-09-21

Applicant: NOVARTIS AG

Inventor： Badry Bursulaya ,  Andreas Fisch ,  James Paul Lajiness ,  Rainer Machauer ,  Swapnil Malekar ,  Hank Michael James Petrassi ,  Farshad Ramazani ,  Anne-Catherine Remond ,  Thomas Ullrich ,  Peggy Usselmann ,  Eric Vangrevelinghe

IPC: A61K31/416 ,  C07D231/56 ,  A61K9/00 ,  A61K9/16 ,  A61K31/454 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12

Abstract: The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

公开(公告)号：US20210177824A1

公开(公告)日：2021-06-17

申请号：US16761779

申请日：2018-11-08

Applicant: NOVARTIS AG

Inventor： Carlo Castagnoli ,  Andreas Fisch ,  Mathilde Lorscheider ,  Manjali Laxman Neharkar ,  Bernd Ulrich Riebesehl

IPC: A61K31/4525 ,  A61K9/08 ,  A61K47/10 ,  A61K47/20 ,  A61K47/32 ,  A61K45/06 ,  A61K9/00

Abstract: The present invention relates to a pharmaceutical composition comprising an aqueous suspension of: (i) crystalline N-(3,4-dichlorophenyl)-3-(pyridin-4-yl)-7-oxabicyclo[2.2.1]heptane-2-carboxamide or a pharmaceutically acceptable salt thereof; and (ii) a surfactant comprising a water-soluble co-polymer characterized by >5% solubility in water at 25° C. The compositions provide extended release of N-(3,4-dichlorophenyl)-3-(pyridin-4-yl)-7-oxabicyclo[2.2.1] heptane-2-carboxamide, and are suitable for intra-articular injection to a joint of a patient suffering from arthritis, joint injury or cartilage injury.

公开(公告)号：US10919887B2

公开(公告)日：2021-02-16

申请号：US15762724

申请日：2016-09-20

Applicant: Novartis AG

Inventor： Eric Aubin ,  Anthony Casarez ,  Andreas Fisch ,  Zaixing Li ,  Mika Lindvall ,  Heinz Ernst Moser ,  Michael Mutz ,  Folkert Reck ,  Bernd Ulrich Riebesehl ,  Marc Schoenhentz ,  Vijay Sethuraman ,  Robert Lowell Simmons

IPC: C07D417/14 ,  A61P31/04

Abstract: The invention provides new solid forms, salts and polymorphs of 1-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)-1-sulfoazetidin-3-yl)amino)ethylidene)amino)oxy)cyclopropanecarboxylic acid (referred to herein as Compound X), pharmaceutical compositions containing them, and processes for their manufacture and use in therapy.

公开(公告)号：US10766894B2

公开(公告)日：2020-09-08

申请号：US16335496

申请日：2017-09-21

Applicant: NOVARTIS AG

Inventor： Badry Bursulaya ,  Andreas Fisch ,  James Paul Lajiness ,  Rainer Machauer ,  Swapnil Malekar ,  Hank Michael James Petrassi ,  Farshad Ramazani ,  Anne-Catherine Remond ,  Thomas Ullrich ,  Peggy Usselmann ,  Eric Vangrevelinghe

IPC: C07D471/04 ,  A61P21/00 ,  A61K9/00 ,  A61K9/50 ,  A61K31/437 ,  A61K31/496 ,  A61K31/538

Abstract: The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.